Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: The Business Research Company | PRODUCT CODE: 1210182

Cover Image

PUBLISHER: The Business Research Company | PRODUCT CODE: 1210182

Biosimilar Lymphocyte Modulator Global Market Report 2023

Published: Pre-Order
PAGES: 250 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 5000
PDF (Site License)
USD 7500
PDF (Enterprise License)
USD 10000

Add to Cart

“Biosimilar Lymphocyte Modulator Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biosimilar lymphocyte modulator market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biosimilar lymphocyte modulator ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The biosimilar lymphocyte modulator market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Drug: Campath-1H; Natalizumab Biosimilar; Efalizumab - A1089-Anti-CD11a Bisoimilar; Anti-CD38 Daratumumab Biosimilar; Anti-CS1 Elotuzumab Bisoimilar

2) Distribution Channel: Online Pharmacies; direct to consumer

3) By Disease: Arthritis; Diabetes; Multiple Myeloma; Enterocolitis; Multiple Sclerosis; Psoriasis; Other Diseases

Companies Mentioned: Pfizer; Biogen; Genentech; Novartis; Celltrion

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the biosimilar lymphocyte modulator market are: Pfizer, Biogen, Genentech, Novartis, and Celltrion.

The global biosimilar lymphocyte modulator market is expected to grow from $1.16 billion in 2021 to $1.34 billion in 2022 at a compound annual growth rate (CAGR) of 15.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services effecting many markets across the globe. The biosimilar lymphocyte modulator market is expected to reach $2.10 billion in 2026 at a CAGR of 11.8%.

The biosimilar lymphocyte modulator market consists of sales of roasted coffee, coffee concentrates, coffee extracts, flavorings, and syrups. Values in this market are: 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Biosimilar lymphocyte modulator refers to immune regulating lymphocyte modulators that manufacture lymphocyte modulator biosimilars. Lymphocyte modulators are intended as an aid in the treatment for cancer and autoimmune diseases, and for regulating carotene intake in humans with a weak immune system.

North America was the largest region in the biosimilar lymphocyte modulator market in 2022. Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the biosimilar lymphocyte modulator market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types of drugs in biosimilar lymphocyte modulators are Campath-1H, natalizumab biosimilar, efalizumab - A1089-anti-CD11A biosimilar, anti-CD38 daratumumab biosimilar, anti-CS1 elotuzumab biosimilar. Campath is a prescription medication used to treat the symptoms of CLL. Campath can be taken on its own or in combination with other drugs. The different diseases include arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, psoriasis, and others. By distribution channel, it is segmented into online Pharmacies and direct to consumer.

Immunotherapy combined with other cancer treatments is expected to drive the growth of the biosimilar lymphocyte modulators market. The combination of immunotherapies or pairing of immunotherapies with other types of cancer treatments, such as chemotherapy or radiation, enhances the benefit associated with lymphocyte modulators. In December 2021, according to a study conducted by the researchers at Washington University School of Medicine in St. Louis, pre-activated natural killer cells will have been shown in a limited clinical trial to be helpful for some adolescents and young adults with recurrent AML who have few other therapeutic choices. Combining the therapies helps To determine whether alternative chemotherapy can improve the killing of leukemia cells, researchers have combined memory-like natural killer cells. The combination approach, therefore, saves patients' lives from a life-threatening reaction of the immune system, thereby driving the growth of the lymphocyte modulator market.

The shortage of raw material for lymphocyte modulator drugs is expected to restrict the growth of the biosimilar lymphocyte modulator market. Drug shortages are due to several factors including challenges in acquiring raw materials, manufacturing problems, regulatory issues, business decisions, and numerous disturbances within the supply chain. They adversely affect patient care by causing the replacement of safe and effective therapies with elective medicines, compromising or delaying medical procedures, or causing medication errors. The American Society of Haematology, an association comprising clinical scientists and physicians that provides care to patients in diverse settings, sent a letter to USFDA highlighting the issue of the shortage of critical hematologic drugs such as etoposide and methotrexate, which have no alternatives. Mainly the drug etoposide, which is a chemotherapeutic drug, is a crucial component in treatment regimens designed to be curative for life-threatening conditions including leukemia and lymphomas. Due to the shortage, some patients have received less effective treatment. Thus, the raw material shortages cause delayed and compromised medical treatments and also result in limiting the growth of the market.

Tumor-Infiltrating Lymphocyte Immunotherapy has been gaining popularity in recent times because of its positive results in anti-cancer treatments. Tumor-infiltrating lymphocytes (TILs) comprise of all lymphocytic cell populaces that have occupied the tumor tissue. TILs have been depicted in various solid tumors including breast cancer, and are emerging as a significant biomarker in predicting the efficacy and result of treatment. Due to promising results, many companies have started launching TIL technologies. For instance, in January 2020, Lovance Biotherapeutics, a US-based start-up company, licensed TALEN technology from Cellectis to develop gene-editing tumor-infiltrating lymphocytes (TIL) to treat several cancer indications. Other companies investing in TIL technology are Optera Therapeutics Corp and TILT Biotherapeutics.

In July 2020, Cytocom, Inc., a US-based immunotherapy generating company, announced the acquisition of ImQuest Life Sciences, Inc. for an undisclosed sum. The deal is expected to support Cytocom's vision of strategic growth and strengthen internal drug development programs with new assets and secure revenue-generating operations, scientific resources, and tools and capacity. ImQuest Life Sciences is a US-based company with leading drug discovery and development. The company was founded in 2004.

The countries covered in the biosimilar lymphocyte modulator market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified).

The revenues for a specified geography are consumption values - that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products.

The biosimilar lymphocyte modulator market research report is one of a series of new reports from The Business Research Company that provides biosimilar lymphocyte modulator market statistics, including biosimilar lymphocyte modulator industry global market size, regional shares, competitors with a biosimilar lymphocyte modulator market share, detailed biosimilar lymphocyte modulator market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar lymphocyte modulator industry. This biosimilar lymphocyte modulator market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Product Code: r2035

Table of Contents

1. Executive Summary

2. Biosimilar Lymphocyte Modulator Market Characteristics

3. Biosimilar Lymphocyte Modulator Market Trends And Strategies

4. Biosimilar Lymphocyte Modulator Market - Macro Economic Scenario

4.1 COVID-19 Impact On Biosimilar Lymphocyte Modulator Market

4.2 Ukraine-Russia War Impact On Biosimilar Lymphocyte Modulator Market

4.3 Impact Of High Inflation On Biosimilar Lymphocyte Modulator Market

5. Biosimilar Lymphocyte Modulator Market Size And Growth

  • 5.1. Global Biosimilar Lymphocyte Modulator Historic Market, 2017-2022, $ Billion
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints On The Market
  • 5.2. Global Biosimilar Lymphocyte Modulator Forecast Market, 2022-2027F, 2032F, $ Billion
    • 5.2.1. Drivers Of The Market
    • 5.2.2. Restraints On the Market

6. Biosimilar Lymphocyte Modulator Market Segmentation

  • 6.1. Global Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Campath-1H
  • Natalizumab Biosimilar
  • Efalizumab - A1089-Anti-CD11a Bisoimilar
  • Anti-CD38 daratumumab Biosimilar
  • Anti-CS1 elotuzumab Bisoimilar
  • 6.2. Global Biosimilar Lymphocyte Modulator Market, Segmentation By Distribtuion, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Online Pharmacies
  • Direct to Consumers
  • 6.3. Global Biosimilar Lymphocyte Modulator Market, Segmentation By Disease, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Arthritis
  • Diabetes
  • Multiple Myeloma
  • Enterocolitis
  • Multiple Sclerosis
  • Psoriasis
  • Other Diseases

7. Biosimilar Lymphocyte Modulator Market Regional And Country Analysis

  • 7.1. Global Biosimilar Lymphocyte Modulator Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 7.2. Global Biosimilar Lymphocyte Modulator Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Biosimilar Lymphocyte Modulator Market

  • 8.1. Asia-Pacific Biosimilar Lymphocyte Modulator Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Biosimilar Lymphocyte Modulator Market

  • 9.1. China Biosimilar Lymphocyte Modulator Market Overview
  • 9.2. China Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Biosimilar Lymphocyte Modulator Market

  • 10.1. India Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Biosimilar Lymphocyte Modulator Market

  • 11.1. Japan Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Biosimilar Lymphocyte Modulator Market

  • 12.1. Australia Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Biosimilar Lymphocyte Modulator Market

  • 13.1. Indonesia Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Biosimilar Lymphocyte Modulator Market

  • 14.1. South Korea Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Biosimilar Lymphocyte Modulator Market

  • 15.1. Western Europe Biosimilar Lymphocyte Modulator Market Overview
  • 15.2. Western Europe Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Biosimilar Lymphocyte Modulator Market

  • 16.1. UK Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Biosimilar Lymphocyte Modulator Market

  • 17.1. Germany Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Biosimilar Lymphocyte Modulator Market

  • 18.1. France Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Biosimilar Lymphocyte Modulator Market

  • 19.1. Eastern Europe Biosimilar Lymphocyte Modulator Market Overview
  • 19.2. Eastern Europe Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Biosimilar Lymphocyte Modulator Market

  • 20.1. Russia Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Biosimilar Lymphocyte Modulator Market

  • 21.1. North America Biosimilar Lymphocyte Modulator Market Overview
  • 21.2. North America Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Biosimilar Lymphocyte Modulator Market

  • 22.1. USA Biosimilar Lymphocyte Modulator Market Overview
  • 22.2. USA Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Biosimilar Lymphocyte Modulator Market

  • 23.1. South America Biosimilar Lymphocyte Modulator Market Overview
  • 23.2. South America Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Biosimilar Lymphocyte Modulator Market

  • 24.1. Brazil Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Biosimilar Lymphocyte Modulator Market

  • 25.1. Middle East Biosimilar Lymphocyte Modulator Market Overview
  • 25.2. Middle East Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Biosimilar Lymphocyte Modulator Market

  • 26.1. Africa Biosimilar Lymphocyte Modulator Market Overview
  • 26.2. Africa Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Biosimilar Lymphocyte Modulator Market Competitive Landscape And Company Profiles

  • 27.1. Biosimilar Lymphocyte Modulator Market Competitive Landscape
  • 27.2. Biosimilar Lymphocyte Modulator Market Company Profiles
    • 27.2.1. Pfizer
      • 27.2.1.1. Overview
      • 27.2.1.2. Products and Services
      • 27.2.1.3. Strategy
      • 27.2.1.4. Financial Performance
    • 27.2.2. Biogen
      • 27.2.2.1. Overview
      • 27.2.2.2. Products and Services
      • 27.2.2.3. Strategy
      • 27.2.2.4. Financial Performance
    • 27.2.3. Genentech
      • 27.2.3.1. Overview
      • 27.2.3.2. Products and Services
      • 27.2.3.3. Strategy
      • 27.2.3.4. Financial Performance
    • 27.2.4. Novartis
      • 27.2.4.1. Overview
      • 27.2.4.2. Products and Services
      • 27.2.4.3. Strategy
      • 27.2.4.4. Financial Performance
    • 27.2.5. Celltrion
      • 27.2.5.1. Overview
      • 27.2.5.2. Products and Services
      • 27.2.5.3. Strategy
      • 27.2.5.4. Financial Performance

28. Biosimilar Lymphocyte Modulator Pipeline Analysis

29. Key Mergers And Acquisitions In The Biosimilar Lymphocyte Modulator Market

30. Biosimilar Lymphocyte Modulator Market Future Outlook and Potential Analysis

31. Appendix

  • 31.1. Abbreviations
  • 31.2. Currencies
  • 31.3. Historic And Forecast Inflation Rates
  • 31.4. Research Inquiries
  • 31.5. The Business Research Company
  • 31.6. Copyright And Disclaimer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!